• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study.

作者信息

Raimondo Annunziata, Amerio Paolo, Balato Anna, Cusano Francesco, Fargnoli Maria Concetta, Guarneri Claudio, Ligrone Luigi, Megna Matteo, Musumeci Maria Letizia, Puca Rosa Valentina, Uzzauto Maria Teresa, Lembo Serena

机构信息

Department of Medicine Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.

Dermatology Unit, University of G. D'Annunzio, Chieti, Italy.

出版信息

J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e287-e289. doi: 10.1111/jdv.20341. Epub 2024 Sep 13.

DOI:10.1111/jdv.20341
PMID:39269027
Abstract
摘要

相似文献

1
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study.司库奇尤单抗在潜伏性结核感染银屑病患者中的疗效和安全性：一项多中心真实世界研究。
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e287-e289. doi: 10.1111/jdv.20341. Epub 2024 Sep 13.
2
Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.未进行化学预防的潜伏性结核感染银屑病患者使用白细胞介素抑制剂的安全性：一项系统评价
Acta Derm Venereol. 2025 Mar 3;105:adv42081. doi: 10.2340/actadv.v105.42081.
3
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.司库奇尤单抗治疗中重度多难治性克罗恩病患者的真实世界有效性和安全性：一项比利时多中心队列研究
Inflamm Bowel Dis. 2024 Dec 5;30(12):2289-2296. doi: 10.1093/ibd/izad315.
4
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.司库奇尤单抗在银屑病患者中的真实世界安全性和有效性：一项多中心、回顾性、非干预性研究
Actas Dermosifiliogr. 2025 Feb;116(2):125-133. doi: 10.1016/j.ad.2024.02.030. Epub 2024 Mar 6.
5
Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas.真实世界数据显示，白细胞介素23（IL23）抑制剂古塞库单抗和司库奇尤单抗在银屑病关节炎及难治性部位具有高度疗效。
Int J Dermatol. 2023 Nov;62(11):1404-1413. doi: 10.1111/ijd.16849. Epub 2023 Sep 25.
6
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.瑞莎珠单抗治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 2随机临床试验的100周结果
Rheumatol Ther. 2024 Jun;11(3):633-648. doi: 10.1007/s40744-024-00657-2. Epub 2024 Mar 18.
7
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.意大利一项为期 28 周的回顾性研究：真实世界中古塞库单抗、里莎鲁单抗和替西珠单抗的间接比较。
J Dermatolog Treat. 2022 Sep;33(6):2813-2820. doi: 10.1080/09546634.2022.2081655. Epub 2022 May 29.
8
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.瑞莎珠单抗治疗活动性银屑病关节炎的疗效和安全性：3期KEEPsAKE 1随机临床试验的100周结果
Rheumatol Ther. 2024 Jun;11(3):617-632. doi: 10.1007/s40744-024-00654-5. Epub 2024 Mar 18.
9
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials.司库奇尤单抗治疗银屑病患者的长期安全性：来自临床试验的综合分析
Dermatol Ther (Heidelb). 2024 Sep;14(9):2523-2538. doi: 10.1007/s13555-024-01238-5. Epub 2024 Aug 17.
10
Risankizumab in Adults with Psoriatic Arthritis.里莎珠单抗治疗成人银屑病关节炎。
Skin Therapy Lett. 2023 Nov;28(6):1-6.

引用本文的文献

1
Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers.探索古塞库单抗和司库奇尤单抗对HIV阳性患者银屑病的影响：来自四个意大利中心的见解
Australas J Dermatol. 2025 Jun;66(4):215-219. doi: 10.1111/ajd.14467. Epub 2025 Apr 3.
2
Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.未进行化学预防的潜伏性结核感染银屑病患者使用白细胞介素抑制剂的安全性：一项系统评价
Acta Derm Venereol. 2025 Mar 3;105:adv42081. doi: 10.2340/actadv.v105.42081.